Anti-spasticity agents for multiple sclerosis-Reference-Cited by-同舟云学术

Anti-spasticity agents for multiple sclerosis

Published:2003-10-20 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Shakespeare David¹,Boggild Mike²,Young Carolyn A²

Affiliation:

1. Lancashire Teaching Hospitals Trust; Neuro-rehabilitation Unit; 32A Watling Street Rd Preston Lancashire UK PR2 8DY

2. The Walton Centre for Neurology & Neurosurgery; Lower Lane Fazakerley Liverpool UK L9 7LJ

Publisher

Wiley

Subject

Pharmacology (medical)

Reference183 articles.

1. Effects of GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study & rehabilitation;Basmajian;American Journal of Physical Medicine,1974

2. Lioresal (baclofen) treatment of spasticity in multiple sclerosis;Basmajian;American Journal of Physical Medicine,1975

3. Ketazolam treatment for spasticity: double-blind study of a new drug;Basmajian;Archives of Physical Medicine & Rehabilitation,1984

4. Ketazolam once daily for spasticity: double-blind cross-over study;Basmajian;Archives of Physical Medicine and Rehabilitation,1986

5. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis;Bass;Canadian Journal of Neurological Sciences,1988

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-09

2. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies;BMJ;2023-08-30

3. Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels;Pharmaceuticals;2023-07-07

4. Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases;BioFactors;2023-01-13

5. Multiple Sklerose;Arzneiverordnungs-Report 2023;2023